Beacon reported that it is preparing a biologics license application after positive results from its pivotal trial in X-linked retinitis pigmentosa. The company described the clinical readout as meeting an FDA-endorsed primary endpoint tied to low-luminance visual acuity, with both dose cohorts showing improvements relative to an untreated control. The announcement reinforces a near-term regulatory trajectory for the XLRP gene therapy category. It also adds to investor focus on how gene therapy efficacy signals are translating into endpoints used by regulators and ad boards. For the field, Beacon’s move toward a BLA also sharpens the competitive clock, as developers evaluate how quickly they can close the gap between pivotal trial reporting and regulatory submission readiness.